$-0.03
(Market cap
$5 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
3.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
1.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.1
-
Face value
--
-
Shares outstanding
3,652,285
10 Years Aggregate
CFO
$-124.24 Mln
EBITDA
$-136.06 Mln
Net Profit
$-200.00 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Pulmatrix (PULM)
| -33.2 | -13.9 | 9.6 | -69.3 | -15.2 | -38.1 | -41.8 |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Pulmatrix (PULM)
| -68.1 | 271.2 | -52.1 | -63.2 | 38.4 | -64.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Pulmatrix (PULM)
|
1.5 | 5.5 | 0.0 | -4.0 | -- | -126.1 | -- | 3.4 |
| 84.9 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 246.7 | 16,614.0 | 1,054.4 | 755.9 | 5.7 | -- | 19.4 | 10.1 | |
| 72.3 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.2 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 105.3 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 350.5 | 10,258.4 | 440.5 | 241.5 | 33.4 | 18.7 | 42.2 | 7.3 | |
| 534.5 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 603.9 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 348.4 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Pulmatrix (PULM)
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered... dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts. Read more
-
President, CEO & Director
Mr. Teofilo David Raad MBA
-
President, CEO & Director
Mr. Teofilo David Raad MBA
-
Headquarters
Framingham, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Pulmatrix (PULM)
What is the current share price of Pulmatrix Inc (PULM) Today?
The share price of Pulmatrix Inc (PULM) is $1.49 (NASDAQ) as of 28-Aug-2026 11:28 EDT. Pulmatrix Inc (PULM) has given a return of -15.16% in the last 3 years.
What is the current PB & PE ratio of Pulmatrix Inc (PULM)?
Since, TTM earnings of Pulmatrix Inc (PULM) is negative, P/E ratio is not available.
The P/B ratio of Pulmatrix Inc (PULM) is 3.44 times as on 21-Aug-2026, a 36 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.58 |
2.14 |
2024 |
-2.67 |
2.85 |
2023 |
-0.48 |
0.38 |
2022 |
-0.75 |
0.45 |
2021 |
-0.06 |
0.03 |
What is the 52 Week High and Low of Pulmatrix Inc (PULM)?
The 52-week high and low of Pulmatrix Inc (PULM) are Rs 5.50 and Rs 1.16 as of 29-Aug-2026.
What is the market cap of Pulmatrix Inc (PULM)?
Pulmatrix Inc (PULM) has a market capitalisation of $ 5 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Pulmatrix Inc (PULM)?
Before investing in Pulmatrix Inc (PULM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.